Table 1 Characteristics of the study population

Males/Females

39/11

13/5 ^¥

15/3 ^&

11/9

6/18^{¥ &}

Age (yrs)

50 ± 9 (24–68)

47 ± 10 (24–67)

51 ± 8 (35–68)

54 ± 8 (36–65)

51 ± 11 (24–66)

BMI (kg/m2)

26 ± 5 (17–40)

25 ± 4 (20–32)

27 ± 6 (17–41)

27 ± 3 (21–34)

25 ± 5 (18–37)

MELD Score

13 ± 5 (7–33)

9 ± 2 (7–13) ^#

12 ± 2 (8–18) §

19 ± 6 (12–33) ^{# §}

n.a.

 - MELD < 15

38 (76%)

18 (100%)

17 (94%)

3 (21%)

 - MELD > 15

12 (24%)

0 (0%)

1 (6%)

11 (79%)

Etiology

n.a.

 - Alcohol

36 (72%)

10 (56%)

13 (72%)

13 (93%)

 - Hepatitis B

1 (2%)

1 (6%)

-

| -

 - Hemochromatosis

1 (2%)

1 (6%)

-

I -

 - PSC

4 (8%)

3 (17%)

1 (6%)

| -

 - Unknown

1 (2%)

-

1 (6%)

| -

 - AIH

1 (2%)

1 (6%)

-

1 -

 - Hepatitis C

4 (8%)

1 (6%)

2 (11%)

1 (7%)

 - Wilson's disease

2 (4%)

1 (6%)

1 (6%)

| -

Ascites

n.a.

 - None

24 (48%)

17 (94%) ^{% #}

6 (33%) ^%

1 (7%) ^#

 - Mild

11 (22%)

1 (6%) ^%

8 (44%) ^%

2 (14%)

- Moderate

15 (30%)

-

4 (22%) ^§

11 (79%) ^§

Hepatic Encephalopathy

n.a.

 - None

43 (86%)

18 (100%)

17 (94%) ^§

8 (57%) ^§

 - Stage I-II

6 (12%)

-

1 (6%)

5 (36%)

 - Stage III-IV

1 (2%)

-

-

1 (7%)

Portal Hypertension

46/50 (92%)

14/18 (78%)

18/18 (100%)

14/14 (100%)

n.a.

Total Bilirubin (mg/dL)

3.4 ± 6.1 (0.4-36.5)*

1.1 ± 0.6 (0.5-2.6) ^#

1.9 ± 1.3 (0.4-6.4) ^§

8.4 ± 10.1 (2.2-36.5) ^{# §$}

0.5 ± 0.2 (0.2-1.5) * ^$

Albumin (g/dL)

3.6 ± 0.7 (2.3-5.2)*

4.4 ± 0.3 (4.0-5.2)^{% #}

3.4 ± 0.5 (2.8-4.5) ^{% &}

3.1 ± 0.5 (2.3-3.8)^#$

4.5 ± 0.4 (3.7-5.2) * ^&$

Prothrombin Time (%)

62 ±18 (32–104)*

77 ± 14 (52–104)^{% # ¥}

61 ± 13 (42–88) ^{% §&}

45 ± 12(32–73)^{# §$}

99 ± 10 (72–114) * ^{¥ & $}

CRP (mg/dL)

9 ± 12 (3–70)*

3 ± 3 (3–11) ^#

9 ± 8 (6–27)

19 ±19(3–70)^{# $}

2 ± 2 (3–9) * ^$

Cr (mg/dL)

0.8 ± 0.5-1.6)

0.8 ± 0.2 (0.6-1.4)

0.7 ± 0;2 (0;5–1;1)

0.9 ± 0.3 (0.5-1.6)

0.8: ± 0. 1(0.6–1.0)

CysC (mg/dL)

1.1 ±0.5 (0.6-3.9)*

1.0 ± 0.4 (0.6-2.4)

0.9 ± 0.3 (0.7-1.7)

1.5 ± 0.8 (0.5-3.9) ^$

0.7 ± 0.1 (0.5-1.0)* ^$